Intracoronary Radiation Therapy Using Re-188 after percutaneous Coronary Angioplasty

경피적 관동맥혈관성형술 후 Re-188을 이용한 혈관 내 방사선조사요법

  • Chae, In-Ho (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Lee, Myoung-Mook (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Lee, Dong-Soo (Department of Nuclear Medicine, Seoul National University College of Medicine)
  • 채인호 (서울대학교 의과대학 내과학교실) ;
  • 이명묵 (서울대학교 의과대학 내과학교실) ;
  • 이동수 (서울대학교 의과대학 핵의학교실)
  • Published : 1999.05.21

Abstract

Percutaneous coronary angioplasty is well established therapeutic modality in the management of coronary artery disease. However, the high restenosis rate of 30 to 50% limits its usefulness. The principal mechanism of restenosis, intimal hyperplasia, is the proliferative response of vessel wall to injury, which consists largely of smooth muscle cells. A large body of animal investigations and a limited number of clinical studies have established the ability of ionizing radiation to reduce neointimal proliferation and restenosis rate significantly. Human studies have been reported that intravascular radiation after first restenosis inhibits a second restenosis. Encouraged by these reports, we are also conducting a double blind, placebo-controlled, randomized trial to evaluate this new therapeutic modality in patients with coronary artery stenosis. The objective of our trial is to determine the safety and efficacy of catheter-based solutional beta emitting radioisotope system in preventing restenosis after angioplasty. This review describes the vascular brachytherapy systems and isotopes that have been utilized in the initial clinical trials performed in this area of post PTCA coronary restenosis. The results of many worldwide ongoing clinical trials will determine whether this new technology will change the future practice of vascular intervention.

Keywords